全身免疫炎症指数在实体癌中的应用研究进展  

Research progress on application of systemic immune inflammatory index in solid cancers

作　　者：许召君 张成武 马晓明[1,2] Xu Zhaojun;Zhang Chengwu;Ma Xiaoming(Graduate School of Qinghai University,Xining 810001,China)

机构地区：[1]青海大学研究生院,西宁810001 [2]青海大学附属医院胃肠外科,西宁810001

出　　处：《新医学》2023年第2期110-114,共5页Journal of New Medicine

基　　金：青海省肿瘤临床医学研究中心建设(2021ZY006)。

摘　　要：全球死亡人数排名前几位的致命癌症部位,主要包括肺癌、胃癌、肝癌、乳腺癌和结肠癌。近年来越来越多的研究表明,癌症相关性炎症在癌症的发生、发展和预后中起着至关重要的作用,如中性粒细胞/淋巴细胞、单核细胞/淋巴细胞、血小板/淋巴细胞。2014年首次定义了全身免疫炎症指数(SII),其结合外周血小板、淋巴细胞和中性粒细胞的综合预后参数,较单一的炎症指标更全面地反映了免疫状态和宿主炎症的平衡等方面,在预测癌症预后方面表现出明显的优势。该文就SII在常见的5种实体癌预后中的应用进行综述,为临床上评估癌症预后提供依据。The top deadly cancer sites in terms of global deaths are lung,stomach,liver,breast and colon cancers.In recent years,more and more studies have shown that cancer-related inflammation plays a crucial role in the development and prognosis of the cancer,such as neutrophil-lymphocyte ratio,monocyte-lymphocyte ratio and platelet-lymphocyte ratio.In 2014,the systemic immune inflammatory index(SII)was first defined.SII combined with peripheral platelets,lymphocytes and neutrophils serves as a comprehensive prognostic parameter,which reflects the balance of immune status and host inflammation more comprehensively than a single inflammatory index.Furthermore,it shows obvious advantages in predicting cancer prognosis.In this article,the application of SII in the prognosis of five common solid cancers was reviewed,aiming to provide the basis for clinical evaluation of cancer prognosis.

关 键 词：全身免疫炎症指数 肺癌 胃癌 肝癌 乳腺癌 结肠癌 

分 类 号：R730.3[医药卫生—肿瘤]